Cheshire orphan-drug maker Alexion Pharmaceuticals Inc. completed its $1.1 billion buyout of Enobia Pharma Corp., a Cambridge, Mass., firm developing treatments for rare, potentially fatal metabolic diseases.
Alexion announced on Dec. 28 plans to buy Enobia for $610 million cash and another $470 million if Enobia achieves specific research and marketing milestones with its drugs.
Goldman Sachs & Co. was Alexion’s financial advisor, while Ropes and Gray LLP was lead legal counsel.
Cassels Brock & Blackwell LLP was Alexion’s Canadian legal counsel.
